Literature DB >> 24013261

Pars plana vitrectomy for vitreomacular traction syndrome: a systematic review and metaanalysis of safety and efficacy.

Timothy L Jackson1, Elena Nicod, Aris Angelis, Federico Grimaccia, Andrew T Prevost, Andrew R H Simpson, Panos Kanavos.   

Abstract

PURPOSE: To determine the safety and efficacy of pars plana vitrectomy for vitreomacular traction.
METHODS: Articles reporting visual acuity change before and after pars plana vitrectomy were selected using a systematic literature review with predefined eligibility criteria. Visual acuities were converted to logarithm of the minimum angle of resolution (logMAR), weighted for study size, and pooled across studies. Safety outcomes were also pooled across studies.
RESULTS: Twenty-one of 460 articles were eligible. Mean (±standard deviation) logMAR visual acuity improved from 0.67 ± 0.55 to 0.42 ± 0.45 (n = 259 eyes) after pars plana vitrectomy (from 20/94 to 20/53 Snellen). In series of at least 20 eyes, mean visual acuity improved in all 5 studies (sign test, P = 0.0625). Of 392 eyes, 9.2% lost visual acuity, 11.7% were unchanged, and 64.3% improved; 32.9% of 217 eyes gained ≥2 Snellen lines. The most common postoperative complications were cataract (34.7% of 304 eyes; 63.2% of 68 phakic eyes), epiretinal membrane (5.7% of 348 eyes), and retinal detachment (4.6% of 348 eyes). Cataract surgery was undertaken in 10.5% of eyes.
CONCLUSION: The visual acuity gains after pars plana vitrectomy for vitreomacular traction are relatively modest, but visual acuity change may not fully reflect symptomatic relief.

Entities:  

Mesh:

Year:  2013        PMID: 24013261     DOI: 10.1097/IAE.0b013e3182a6b3e2

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  25 in total

1.  Spectrum of morphological and visual changes due to vitreomacular interface disorders encountered in a large consecutive cohort of patients.

Authors:  W Fusi-Rubiano; M Awad; R Manjunath; I Elaraoud; N Narendran; Y Yang
Journal:  Eye (Lond)       Date:  2015-01-09       Impact factor: 3.775

2.  A retrospective study of a single practice use of ocriplasmin in the treatment of vitreomacular traction.

Authors:  Victoria Morrison Knudsen; Igor Kozak
Journal:  Saudi J Ophthalmol       Date:  2014-02-19

3.  Vision Preference Value Scale and Patient Preferences in Choosing Therapy for Symptomatic Vitreomacular Interface Abnormality.

Authors:  Marguerite O Linz; Neil M Bressler; Voraporn Chaikitmongkol; Sobha Sivaprasad; Direk Patikulsila; Janejit Choovuthayakorn; Nawat Watanachai; Paradee Kunavisarut; Deepthy Menon; Mongkol Tadarati; Kátia Delalíbera Pacheco; Abanti Sanyal; Adrienne W Scott
Journal:  JAMA Ophthalmol       Date:  2018-06-01       Impact factor: 7.389

4.  The Charles Schepens Lecture: Management Options for Vitreomacular Traction: Use an Individualized Approach.

Authors:  Harry W Flynn; Nidhi Relhan
Journal:  Ophthalmol Retina       Date:  2017 Jan-Feb

5.  Prevalence, characteristics, and pathogenesis of paravascular inner retinal defects associated with epiretinal membranes.

Authors:  Yukiko Miyoshi; Akitaka Tsujikawa; Saki Manabe; Yuki Nakano; Tomoyoshi Fujita; Chieko Shiragami; Kazuyuki Hirooka; Akihito Uji; Yuki Muraoka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-19       Impact factor: 3.117

6.  Cost evaluation of surgical and pharmaceutical options in treatment for vitreomacular adhesions and macular holes.

Authors:  Jonathan S Chang; William E Smiddy
Journal:  Ophthalmology       Date:  2014-05-15       Impact factor: 12.079

7.  A retrospective cohort study in patients with tractional diseases of the vitreomacular interface (ReCoVit).

Authors:  Peter Stalmans
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-22       Impact factor: 3.117

8.  Functional improvement assessed by multifocal electroretinogram after Ocriplasmin treatment for vitreomacular traction.

Authors:  Settimio Rossi; Francesco Testa; Paolo Melillo; Ada Orrico; Michele Della Corte; Francesca Simonelli
Journal:  BMC Ophthalmol       Date:  2016-07-18       Impact factor: 2.209

9.  Vitreomacular traction syndrome.

Authors:  Thiago Gonçalves dos Santos Martins; Thomaz Gonçalves dos Santos Martins; Ever Ernesto Caso Rodriguez; Ana Luiza Fontes de Azevedo Costa
Journal:  Einstein (Sao Paulo)       Date:  2015-05-01

10.  Effectiveness of ocriplasmin in real-world settings: A systematic literature review, meta-analysis, and comparison with randomized trials.

Authors:  Arshad M Khanani; Ryan N Constantine; Koenraad H Blot; Benedicte Lescrauwaet; Peter Szurman
Journal:  Acta Ophthalmol       Date:  2020-12-26       Impact factor: 3.761

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.